论文部分内容阅读
目的:探讨细胞因子诱导的杀伤(cytokine-induced killer,CIK)细胞联合化疗对胃癌患者的疗效。方法:计算机检索Pub Med、EMBase、Web of Science、Cochrane数据库、中国期刊全文数据库和维普数据库,收集1990年1月到2014年3月发表的符合要求的随机对照试验或非随机同期对照试验,应用Revman 5.2软件进行Meta分析。结果:共纳入5项研究、306名胃癌患者。Meta分析结果提示,与单纯化疗相比,CIK细胞联合化疗能够提高患者近、远期疗效。肿瘤近期缓解率:RR=2.14,95%CI:1.20~3.79,P=0.01,I2=0%。远期效应:1年存活率,RR=1.13,95%CI:1.03~1.24,P=0.09,I2=50%;2年存活率,RR=1.22,95%CI:1.11~1.44,P=0.46,I2=0%;3年存活率,RR=1.34,95%CI:1.10~1.63,P=0.5,I2=0%。无进展生存期:RR=2.65,95%CI:2.29~3.01,P<0.001,I2=98%。结论:CIK细胞联合化疗相对于单纯化疗能提高胃癌患者近、远期疗效,延长患者无进展生存期。
Objective: To investigate the effect of cytokine-induced killer (CIK) cells combined with chemotherapy on patients with gastric cancer. METHODS: PubMed, EMBase, Web of Science, Cochrane Database, Chinese Journal Full-text Database and VIP database were searched by computer. Randomized controlled trials or non-randomized controlled trials published from January 1990 to March 2014 were collected. Revman 5.2 software for meta-analysis. Results: Five studies and 306 gastric cancer patients were enrolled. Meta analysis showed that, compared with chemotherapy alone, CIK cells combined with chemotherapy can improve the short-term and long-term efficacy. Recent remission rate of tumor: RR = 2.14, 95% CI: 1.20 ~ 3.79, P = 0.01, I2 = 0%. Long-term effects: 1 year survival rate, RR = 1.13, 95% CI: 1.03-1.24, P = 0.09, I2 = 50%; 2-year survival rate, RR = 1.22, 95% CI: 1.11-1.44, P = 0.46 , I2 = 0%; 3-year survival rate, RR = 1.34, 95% CI: 1.10-1.63, P = 0.5, I2 = 0%. Progression free survival: RR = 2.65, 95% CI: 2.29-3.01, P <0.001, I2 = 98%. Conclusions: Compared with chemotherapy alone, CIK cells combined with chemotherapy can improve the curative effect in patients with gastric cancer and prolong the progression-free survival of patients with gastric cancer.